Trial ID or NCT#

NCT02867384

Status

RECRUITING

Purpose

This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).

Official Title

A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

David Miklos, M.D., Ph.D.
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Hematologist, Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Wen-Kai Weng, MD, PhD
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Lymphoma specialist, Medical oncologist, Multiple myeloma specialist
Associate Professor of Medicine (Blood and Marrow Transplantation) and, by courtesy, of Dermatology at the Stanford University Medical Center
D. Kathryn Tierney
Robert Negrin, M.D.
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation)
Andrew R. Rezvani, M.D.
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Medical oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Lori Muffly, MD, MS
Hematologist, Blood and marrow transplant specialist
Assistant Professor of Medicine (Bone and Marrow Transplantation) at the Stanford University Medical Center
Robert Lowsky, MD
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Juliana Craig
(650) 725-8130